Related Experiment Video
Updated: Jun 26, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
A nuclear beacon of hope: an advanced, metastatic glucagonoma treated with [177Lu]Lu-DOTA-TATE
Martyna Kłosińska1, Joanna Kołodziej2, Adrianna Mróz1
1Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Abstract:
Glucagonoma is a rare pancreatic neuroendocrine tumor (panNET) that can be characterized by increased secretion of glucagon and distinguishing symptoms - glucagonoma syndrome with a typical dermatosis, necrolytic migratory erythema, being its most common manifestation. While surgery and somatostatin analogs remain first-line therapeutic options in panNETs, radioligand therapy with [177Lu]Lu-DOTA-TATE is a recommended second-line palliative treatment in advanced, metastatic cases. However, its prospects and efficacy are still not vastly researched in less frequent neuroendocrine neoplasms. Here, we present an extraordinary case of a metastatic glucagonoma treated with [177Lu]Lu-DOTA-TATE used as a second-line treatment in progressive disease.
Insights
This study highlights a rare case of metastatic glucagonoma, a pancreatic neuroendocrine tumor. [177Lu]Lu-DOTA-TATE showed promise as a second-line treatment for progressive disease.
Area of Science:
- Oncology
- Endocrinology
- Nuclear Medicine
Background:
- Glucagonoma, a rare pancreatic neuroendocrine tumor (panNET), often presents with glucagonoma syndrome, characterized by necrolytic migratory erythema.
- Standard treatments for panNETs include surgery and somatostatin analogs.
- Radioligand therapy with [177Lu]Lu-DOTA-TATE is a recommended second-line option for advanced panNETs, but its use in rarer subtypes like glucagonoma is less explored.
Purpose of the Study:
- To report an exceptional case of metastatic glucagonoma treated with [177Lu]Lu-DOTA-TATE.
- To evaluate the efficacy of [177Lu]Lu-DOTA-TATE as a second-line palliative treatment in a progressive metastatic glucagonoma case.
Main Methods:
- A case study approach was used.
- The patient received [177Lu]Lu-DOTA-TATE as a second-line palliative treatment for progressive metastatic glucagonoma.
Main Results:
- The case involved metastatic glucagonoma, a rare neuroendocrine neoplasm.
- [177Lu]Lu-DOTA-TATE was administered as a second-line therapy for progressive disease.
Conclusions:
- This case demonstrates the potential utility of [177Lu]Lu-DOTA-TATE in managing advanced, metastatic glucagonoma.
- Further research is warranted to establish the efficacy and long-term outcomes of radioligand therapy in less common neuroendocrine neoplasms.
